Tag: treatments

With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sensing and modulation, strengthening its strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

The Vascular Access Devices Market Companies Quadrant delivers a thorough analysis of the global vascular access devices sector. Highlighting prominent players, innovations, and trends, it identifies the top 25 companies as quadrant leaders among over 100 evaluated. Vascular access devices (VADs), crucial for treatments like chemotherapy and dialysis, are set to grow from USD 5.99 billion in 2024 to USD 9.05 billion by 2030 at a 7.1% CAGR, fueled by rising demand and investments despite a skilled professional shortage. Key players include Beckton Dickinson, Teleflex, and ICU Medical, known for expanding portfolios through strategic acquisitions and innovations. The quadrant evaluates companies based on revenue, growth strategies, and product footprint across device types and applications.